These mutations lead to activation of the MAPK signaling pathway, independently of RAS activity, which is suppressed by a negative feedback signal mediated by ERK and results in resistance to anti-EGFR therapy in CRC [56,57]. The gene discussed is EGFR; the disease is colorectal carcinoma.